Sign In
Buy ALXO
$1.67
-0.110 (-6.18%)
At Close: Jun 03, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
08:00am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapie
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 12'th May 2026
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
04:01am, Saturday, 09'th May 2026
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Q1 Earnings Call Highlights
04:07pm, Friday, 08'th May 2026
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-target
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Friday, 08'th May 2026
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable resp
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasda
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
04:05pm, Friday, 17'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel ther
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
08:30am, Monday, 13'th Apr 2026
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
05:36am, Monday, 13'th Apr 2026
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 2,222,798 shares, a gr
ALX Oncology Q4 Earnings Call Highlights
05:05am, Monday, 02'nd Mar 2026
ALX Oncology (NASDAQ: ALXO) outlined progress across its two core programs-CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate ALX2004-while providing updated clinical timelines and fina
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
06:07pm, Friday, 27'th Feb 2026
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
08:00am, Friday, 27'th Feb 2026
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
08:33am, Thursday, 19'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapi
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
08:30am, Thursday, 19'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
